Press Releases
Safety confirmation and observed trends in Covid-19 study build further confidence in Cyxone’s rheumatoid arthritis program
1 Apr, 2022 08:26 CESTCyxone’s CMO departs the company
23 Feb, 2022 08:30 CETRegulatoryYear-end Report 1 January to 31 December 2021
22 Feb, 2022 08:30 CETRegulatoryCyxone announces outcome of the rights issue
25 Jan, 2022 19:31 CETRegulatoryMARCyxone takes next step in Multiple Sclerosis program engaging Contract Development & Manufacturing Organization for production of T20K
18 Jan, 2022 08:46 CET